title: Evaluation of PD-L1 Expression in Tumor Tissue of Patients with Lung Carcinoma and Correlation with Clinical and Demographic Data.
abstract: Lung cancer is the leading world cause of cancer-related death, in both genders, and smoking is the main etiological factor. The discovery of immune checkpoints corroborates the hypothesis that ligands presented in tumors modulate the mechanisms of carcinogenesis and the immune activity of tumor microenvironment. Among the most studied coregulatory molecules, PD-1(programmed cell death 1)and its ligand PD-L1(programmed cell death 1 ligand 1)are noteworthy. The present study aims to enhance the understanding of the tumor microenvironment of lung cancer patients who underwent surgery, by means of analysis of PD-L1 expression in tumor cells and in intratumoral immune cells (IICs). It was found that PD-L1 expression was more frequent in tumor cells than in IICs. Collective analysis by Tissue Microarray Assay (TMA) for PD-L1 expression in tumor cells and IICs did not reproduce the findings for separate individual analysis of tumor tissues. Patients with past history of smoking were more likely to express PD-L1 in tumor cells than those who never smoked. Patients with past history of smoking were less likely to have PD-L1 positive IICs compared to those who had never smoked. The immunohistochemical expression of PD-L1 in tumor cells and IICs did not correlate with survival.
authors.affiliation: Department of Medical Oncology, Barretos Cancer Hospital, Barretos, SP, Brazil.
authors.forename: Gustavo
authors.identifier: 0000-0002-3743-6380
authors.initials: G
authors.lastname: Dix Junqueira Pinto
authors.affiliation: Department of Oncology, Marcio Cunha Hospital, Fundação São Francisco Xavier, Ipatinga, MG, Brazil; Post Graduation Program in Oncology, Barretos Cancer Hospital, Barretos, SP, Brazil.
authors.forename: Luciano
authors.initials: L
authors.lastname: de Souza Viana
authors.affiliation: Post Graduation Program in Oncology, Barretos Cancer Hospital, Barretos, SP, Brazil; Pathology, Clinicas Oncologicas Integradas, Rio de Janeiro, RJ, Brazil.
authors.forename: Cristovam
authors.initials: C
authors.lastname: Scapulatempo Neto
authors.affiliation: Department of Medical Oncology, Barretos Cancer Hospital, Barretos, SP, Brazil; Barretos School of Health Sciences (FACISB), Barretos, SP, Brazil.
authors.forename: Sérgio
authors.initials: S
authors.lastname: Vicente Serrano
mesh_terms: D000328:Adult; D000368:Aged; D015703:Antigens, CD / Q000378:metabolism; D015214:Antigens, Differentiation, Myelomonocytic / Q000378:metabolism; D060890:B7-H1 Antigen / Q000235:genetics / Q000378:metabolism*; D014408:Biomarkers, Tumor; D005260:Female; D015870:Gene Expression; D006801:Humans; D007150:Immunohistochemistry; D008175:Lung Neoplasms / Q000209:etiology* / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D016017:Odds Ratio; D011379:Prognosis; D012307:Risk Factors; D016019:Survival Analysis; D059016:Tumor Microenvironment / Q000235:genetics / Q000276:immunology; D000097382:CD68 Molecule
chemical_list: D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D060890:B7-H1 Antigen; D014408:Biomarkers, Tumor; C067980:CD68 antigen, human; D000097382:CD68 Molecule